The designs of the studies ranged from two to six arms. Eleven studies contained two arms comparing disulfiram to either placebo [14], [32], [34], to no disulfiram [23], [42], to naltrexone [21], [24], [33], [35], to acamprosate [36], or to topiramate [37]. Six studies had three arms. Four of these compared disulfiram to naltrexone and to one other condition: to no disulfiram [13], to acamprosate [22], [40], or to GHB [41]. The control arms in these studies were combined in order to calculate the overall efficacy and the following comparisons: blind versus open-label, supervision versus no supervision, and cocaine versus non cocaine. The control arms were analyzed separately, however, when comparing disulfiram efficacy across the various control conditions. The fifth and sixth studies compared disulfiram to placebo and no disulfiram [27], [39]. In these two studies, the control arms were combined in order to calculate the overall efficacy effect-size. In comparisons of efficacy in blind versus open-label, the control arms were analyzed separately. In addition, for comparisons of cocaine versus non cocaine trials, supervised versus non supervised conditions, and across
